Vascular complications of selected cancer therapies

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 12, 2008, Pages 797-805

  Daher, Iyad N ^a   Yeh, Edward T H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CISPLATIN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; GLYCERYL TRINITRATE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THALIDOMIDE; TUBULIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASODILATOR AGENT; WARFARIN;

ANEMIA; ANGINA PECTORIS; ARTERY EMBOLISM; ARTERY THROMBOSIS; BOLUS INJECTION; BONE MARROW TOXICITY; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CATHETER THROMBOSIS; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY SPASM; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DISEASE MARKER; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; KIDNEY CANCER; KIDNEY INJURY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; MICROANGIOPATHY; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; SOLID TUMOR; ST SEGMENT DEPRESSION; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; TESTIS CANCER; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR ENDOTHELIUM; VASOSPASM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CISPLATIN; FLUOROURACIL; HUMANS; HYPERTENSION; INDOLES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; THALIDOMIDE; THROMBOSIS; VASCULAR DISEASES;

EID: 57049149036     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1375     Document Type: Review

References (70)

1. Hewitt ME et al. (2006) From Cancer Patient To Cancer Survivor: Lost In Transition. Washington, DC: The National Academies Press
2. Death rates by age, sex, race, and underlying cause: United States, 1981-2004 (NMR04a). [http://205.207.175.93/aging/TableViewer/ tableView.aspx?ReportId=424]
3. Yeh ET et al. (2004) Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 109: 3122-3131
4. Yeh ET (2006) Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 57: 485-498
5. van den Belt-Dusebout AW et al. (2006) Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24: 467-475
6. Giordano SH et al. (2005) Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97: 419-424
7. Gradishar WJ and Vokes EE (1990) 5-Fluorouracil cardiotoxicity: A critical review. Ann Oncol 1: 409-414
8. Ranieri G et al. (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem 13: 1845-1857
9. Grem J (1990) Fluorinated pyrimidines. In Cancer Chemotherapy, Principles and Practice, 197-200 (Eds Chabner BA and Collins JM) Philadelphia, PA: JB Lippincott
10. Kikuchi KS et al. (1982) Clinical survey on cardiotoxicity of tegafur (FT-207) - compilation of a nationwide survey [Japanese]. Gan To Kagaku Ryoho 9: 1482-1488
11. Frickhofen N et al. (2002) Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 13: 797-801
12. Labianca R et al. (1982) Cardiac toxicity of 5-fluorouracil: A study on 1,083 patients. Tumori 68: 505-510
13. Gradishar WJ (1990) Catastrophic vascular events in patients receiving 5-fluorouracil based chemotherapy [abstract #1128]. Proc Am Assoc Can Res 31: 190
14. Hansen RM et al. (1996) Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88: 668-674
15. Lokich JJ et al. (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432
16. Poplin EA et al. (2005) Phase III Southwest Oncology Group 9415/ Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: 1819-1825
17. Doll DC et al. (1986) Vascular toxicity associated with antineoplastic agents. J Clin Oncol 4: 1405-1417
18. Tham J and Albertsson M (2004) Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy - three case reports and a review. Acta Oncol 43: 108-112
19. Blom JW et al. (2006) High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patients. Eur J Cancer 42: 410-414
20. Yoshikawa R et al. (2005) Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy. Oncol Rep 13: 627-632
21. Papamichael D et al. (1998) 5-Fluorouracil-induced Raynaud's phenomenon. Eur J Cancer 34: 1983
22. Rezkalla S et al. (1989) Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study. J Clin Oncol 7: 509-514
23. Alter P et al. (2006) Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 4: 1-5
24. Mosseri M et al. (1990) 5-FU induced vasoconstriction in isolated rabbit aortic rings [abstract #2632]. Proc Am Assoc Can Res 30 443
25. Hayward R et al. (2004) Training enhances vascular relaxation after chemotherapy-induced vasoconstriction. Med Sci Sports Exerc 36: 428-434
26. Baerlocher GM et al. (1997) The anti-neoplastic drug 5-fluorouracil produces echinocytosis and affects blood rheology. Br J Haematol 99: 426-432
27. Drevs J et al. (2004) Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24: 1759-1763
28. Cwikiel M et al. (1996) The influence of 5-fluorouracil and methotrexate on vascular endothelium: An experimental study using endothelial cells in the culture. Ann Oncol 7: 731-737
29. Basaki Y et al. (2001) a-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 4: 163-173
30. Ray S et al. (2007) In vitro evaluation of protective effects of ascorbic acid and water extract of Spirulina plantesis (blue green algae) on 5-fluorouracil-induced lipid peroxidation. Acta Pol Pharm 64: 335-344
31. Miller K et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 2666-2676
32. Fernando NH and Hurwitz HI (2004) Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9 (suppl 1) S11-S18
33. Gordon MS and Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69 (Suppl 3): S25-S33
34. Zhu X et al. (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193
35. van Heeckeren WJ et al. (2007) Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: Clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 25: 2993-2995
36. Kabbinavar F et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65
37. Sandler AB et al. (2004) Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10 4258s-4262s
38. Herbst RS and Sandler AB (2004) Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab? Oncologist 9 (suppl 1): S19-S26
39. Ratner M (2004) Genentech discloses safety concerns over Avastin. Nat Biotechnol 22: 1198
40. Roncalli J et al. (2006) Bevacizumab in metastatic colorectal cancer: A left intracardiac thrombotic event. Ann Oncol 17: 1177-1178
41. Yoon S et al. (2006) Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta. Ann Oncol 17: 1851-1852
42. Shah MA et al. (2005) Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23: 2574-2576
43. Seiwert TY et al. (2008) Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 26: 1732-1741
44. Lee S et al. (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130: 691-703
45. Verheul HM and Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7 475-485
46. Kamba T and McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795
47. Fischer C et al. (2007) Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475
48. Roncone D et al. (2007) Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 3: 287-293
49. Frangie C et al. (2007) Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8: 177-178
50. Force T et al. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332-344
51. Motzer RJ et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524
52. Demetri GD et al. (2005) Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract #4000]. J Clin Oncol 23 (suppl): S308
53. Chu TF et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011-2019
54. Kane RC et al. (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278
55. Patel TV et al. (2008) A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100: 282-284
56. Wu S et al. (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 9: 117-123
57. Berliner S et al. (1990) Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 8: 583-586
58. Meinardi MT et al. (2000) Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18: 1725-1732
59. Berger CC et al. (1995) Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A: 2229-2238
60. Doll DC et al. (1986) Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 105: 48-51
61. Rajkumar SV et al. (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17: 775-779
62. Noel JK et al. (2008) Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer: A systematic review of the literature. Med Oncol [doi:10.1007/s12032-008-9039-1]
63. Palumbo A et al. (2008) Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414-423
64. Palumbo A et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367: 825-831
65. Facon T et al. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370: 1209-1218
66. Baz R et al. (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80: 1568-1574
67. Goz M et al. (2008) Arterial thrombosis and thalidomide. J Thromb Thrombolysis 25: 224-226
68. Fanelli M et al. (2003) Thalidomide: A new anticancer drug? Expert Opin Investig Drugs 12: 1211-1225
69. Dimopoulos M et al. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132
70. Richardson PG et al. (2006) Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 6: 1165-1173